CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials
Farasat Kazmi(University of Oxford), Sarah P. Blagden(Churchill Hospital), Simon Lord(University of Oxford), Debashis Sarker(King's College - North Carolina), Andrew Blake(Mary Lyon Centre at MRC Harwell), Kaiser Anam(Guy's Hospital), Thomas Foord, Mark R. Middleton(University of Oxford)
Cited by 1
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
|The Lancet Infectious Diseases|2020|405